Meet Scandinavian Biopharma at Northern European Conference on Travel Medicine (NECTM 7) in Stockholm

From May 2^nd to May 4^th, over 500 delegates will gather in Stockholm for the main Travel medicine conference in 2018.

The conference fosters travel medicine in Europe. NECTM is an association formed by medical medicine associations in the Nordic countries, the United Kingdom, Germany, Ireland and the Netherlands. The conference has a comprehensive scientific program and delegates mainly from northern Europe meet here to discuss common travel health topics and advances in travel medicine.

Key achievements for our ETEC vaccine candidate will be presented during the scientific sessions. Our ETEC vaccine is seen as the most prominent ETEC candidate in clinical development. The vaccine has shown impressive results both in terms of safety and the ability to activate the immune system.

On Thursday 3^rd of May (11:30-11:45) Professor Anu Kantele from Helsinki University will give a presentation about our ongoing clinical phase IIB trial in Benin “OEV-123 - A clinical trial on an oral inactivated etec vaccine, ETVAX”. The day after, Friday 4^th of May (14:30-15:00), Professor Ann-Mari Svennerholm from University of Gothenburg will give a presentation about “Research efforts to develop new enteric vaccines for travelers and populations in endemic countries”.

Please come and visit our booth at NECTM, Clarion Hotel in Stockholm.

Ämnen

Scandinavian Biopharma

Scandinavian Biopharma is a Swedish research-based biotech company specialist in marketing and sales of vaccines, immunoglobulin’s, biodefense, antidotes and diagnostic tests.

Research and development is mainly focused on development of a new oral traveler’s diarrhea vaccine in collaboration with PATH Vaccine Solutions and University of Gothenburg.

www.scandinavianbiopharma.se

Relaterat innehåll

27 Februari 2017 21:03

All 450 participants starting from adults down to 6 months young infants are enrolled in our study in Bangladesh

One and a half year ago a phase I/II randomized, double-blind, placebo-controlled trial was started in Dhaka, Bangladesh. All 450 participantshave now been enrolled and the last child received the vaccine this February. This clinical trial is the first important step toward showing that our vaccine can protect children in the developing world against ETEC diarrhoea.

25 Maj 2017 08:00

Nu tar vi nästa steg mot ett nytt ETEC vaccin

Nu startar vi rekryteringen till vår nästa studie. Tillsammans med forskare från Helsingfors universitet, Göteborgs universitet och Johns Hopkins University ska säkerheten och den kliniska effekten av vårt ETEC-vaccin testas i en placebokontrollerad fas IIb studie. Studien, som löper under minst ett år, ska göras på finska resenärer som ska resa till Benin i Afrika

27 Februari 2017 20:57

Nu har 450 personer mellan 45 år ned till 6 månader vaccinerats i vår studie i Bangladesh

För ett och ett halvt år sedan startade vi vår placebokontrollerade fas I/II-studie i Dhaka, Bangladesh. Studien omfattade cirka 450 personer och nu i februari vaccinerades den sista bebisen i vår studie. Den här kliniska studien är ett viktigt första steg för att visa att vårt vaccin kan förbättra barns chanser att förebygga diarrésjukdomar.